Ozmosi | RPH-001 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

RPH-001

Alternative Names: rph-001, rph001, rph 001
Clinical Status: Inactive
Latest Update: 2025-12-17
Latest Update Note: Clinical Trial Update

Product Description

Bevacizumab Biosimilar

Mechanisms of Action: VEGF Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: TRPHARM
Company Location: Europe
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Colorectal Cancer|Liver Cancer

Phase 2: Non-Small-Cell Lung Cancer|Clear Cell Adenocarcinoma|Clear Cell Sarcoma|Peritoneal Cancer|Transitional Cell Carcinoma|Mucinous Adenocarcinoma|Mesothelioma|Endometrioid Carcinoma|Carcinosarcoma|Ovarian Cancer

Phase 1: Healthy Volunteers|Myeloid, Accelerated Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Juvenile Myelomonocytic Leukemia,|Lymphocytic Chronic B-Cell Leukemia|Myelofibrosis|Chronic, Atypical, BCR-ABL Negative Myeloid Leukemia|Oncology Unspecified|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Breast Cancer|Lymphoma, B-Cell|Acute Myelomonocytic Leukemia|Non-Small-Cell Lung Cancer|Blast Crisis|Leukemia, Plasma Cell|Acute Lymphoid Leukemia|Chronic Lymphoid Leukemia|Preleukemia|Adenocarcinoma|Chronic Myelomonocytic Leukemia|Sarcoma|Multiple Myeloma|Acute Myeloid Leukemia|Myelodysplastic-Myeloproliferative Diseases|Soft Tissue Cancer|Prostate Cancer|Acute Monocytic Leukemia|Myelodysplastic Syndrome|Pancreatic Cancer|Ovarian Cancer|Thrombocytosis|Anemia, Refractory|Breast Diseases|Chronic Myeloid Leukemia|Myeloproliferative Disorders|Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05238831

STUDY00020679

P1

Withdrawn

Soft Tissue Cancer|Prostate Cancer|Sarcoma|Pancreatic Cancer|Ovarian Cancer|Breast Cancer

2026-05-31

4%

2024-11-27

Primary Endpoints|Treatments

NCT03878524

PRIME

P1

Terminated

Pancreatic Cancer|Acute Myelomonocytic Leukemia|Preleukemia|Myelodysplastic Syndrome|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Thrombocytosis|Chronic Lymphoid Leukemia|Myeloid, Accelerated Leukemia|Breast Diseases|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Acute Lymphoid Leukemia|Prostate Cancer|Myelodysplastic-Myeloproliferative Diseases|Breast Cancer|Multiple Myeloma|Myelofibrosis|Chronic Myeloid Leukemia|Lymphoma, B-Cell|Myeloproliferative Disorders|Lymphoma, Non-Hodgkin|Leukemia, Plasma Cell|Chronic, Atypical, BCR-ABL Negative Myeloid Leukemia|Blast Crisis|Juvenile Myelomonocytic Leukemia,|Adenocarcinoma|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Anemia, Refractory

2020-12-10

2024-11-27

Primary Endpoints|Treatments

NCT03659305

СL01011063

P1

Completed

Healthy Volunteers|Oncology Unspecified

2019-01-26

64%

2019-03-22

Primary Completion Date|Study Completion Date|Treatments|Trial Status

NCT03131700

RPH001BEV01

P1

Withdrawn

Healthy Volunteers

2018-01-01

2019-03-21

Treatments

2017-001634-26

2017-001634-26

P1

Unknown status

Non-Small-Cell Lung Cancer

2017-05-29

2025-06-20

Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

NCT07288034

IMMUNO-BIOMAP

P2

Not yet recruiting

Non-Small-Cell Lung Cancer

2028-09-22

2025-12-18

Primary Endpoints|Treatments

NCT05001880

NCI-2021-08573

P2

Recruiting

Mesothelioma

2026-08-20

2025-10-10

Primary Completion Date|Primary Endpoints|Study Completion Date

NCT02364713

MC1365

P2

Terminated

Mucinous Adenocarcinoma|Transitional Cell Carcinoma|Ovarian Cancer|Peritoneal Cancer|Clear Cell Sarcoma|Carcinosarcoma|Clear Cell Adenocarcinoma|Endometrioid Carcinoma

2022-01-13

2025-08-27

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT05863195

The PUMP Trial

P3

Recruiting

Liver Cancer|Colorectal Cancer

2029-06-30

2024-11-27

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title